The UK's GW Pharmaceuticals says that its cannabis-based Sativex proved effective as a long-term therapy for MS-related neuropathic pain. Its shares quickly jumped seven percent on the news. GW Release
The UK's GW Pharmaceuticals says that its cannabis-based Sativex proved effective as a long-term therapy for MS-related neuropathic pain. Its shares quickly jumped seven percent on the news. GW Release